

Klaus Munkholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/687497/publications.pdf>

Version: 2024-02-01

57
papers

2,043
citations

361413

20
h-index

265206

42
g-index

60
all docs

60
docs citations

60
times ranked

2925
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2013, 47, 1119-1133.	3.1	358
2	Cytokines in bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2013, 144, 16-27.	4.1	229
3	Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2016, 21, 216-228.	7.9	120
4	The Bipolar Illness Onset study: research protocol for the BIO cohort study. <i>BMJ Open</i> , 2017, 7, e015462.	1.9	119
5	Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. <i>BMJ Open</i> , 2019, 9, e024886.	1.9	103
6	Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 112-118.	4.1	103
7	Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. <i>Nordic Journal of Psychiatry</i> , 2012, 66, 248-253.	1.3	102
8	Electronic self-monitoring of mood using IT platforms in adult patients with bipolar disorder: A systematic review of the validity and evidence. <i>BMC Psychiatry</i> , 2016, 16, 7.	2.6	80
9	Heart rate variability in bipolar disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 73, 68-80.	6.1	77
10	Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. <i>Brain, Behavior, and Immunity</i> , 2015, 43, 205-213.	4.1	73
11	Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder – Results from a prospective study. <i>Journal of Affective Disorders</i> , 2016, 197, 167-174.	4.1	67
12	Oxidation of Plasma Low-Density Lipoprotein Accelerates Its Accumulation and Degradation in the Arterial Wall In Vivo. <i>Circulation</i> , 1996, 94, 1698-1704.	1.6	59
13	A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. <i>Translational Psychiatry</i> , 2015, 5, e614-e614.	4.8	58
14	Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 257-268.	1.9	51
15	Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. <i>Psychoneuroendocrinology</i> , 2014, 47, 199-211.	2.7	45
16	Increased DNA and RNA damage by oxidation in patients with bipolar I disorder. <i>Translational Psychiatry</i> , 2016, 6, e867-e867.	4.8	42
17	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , 2019, 7, 8.	2.2	39
18	State-related alterations of gene expression in bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2012, 14, 684-696.	1.9	38

#	ARTICLE	IF	CITATIONS
19	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 651-662.	2.3	31
20	State-related differences in heart rate variability in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2017, 84, 169-173.	3.1	27
21	A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 227-236.	4.5	23
22	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. <i>Psychoneuroendocrinology</i> , 2019, 99, 183-190.	2.7	23
23	The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review. <i>Molecular Psychiatry</i> , 2022, 27, 192-201.	7.9	23
24	Reduced mRNA Expression of PTGDS in Peripheral Blood Mononuclear Cells of Rapid-Cycling Bipolar Disorder Patients Compared with Healthy Control Subjects. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu101-pyu101.	2.1	22
25	Consideration of confounding was suboptimal in the reporting of observational studies in psychiatry: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2020, 119, 75-84.	5.0	20
26	Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review. <i>The Cochrane Library</i> , 2020, 2020, CD013597.	2.8	17
27	Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532110676.	2.7	14
28	Individual response to antidepressants for depression in adults—a meta-analysis and simulation study. <i>PLoS ONE</i> , 2020, 15, e0237950.	2.5	13
29	Leukocytes in peripheral blood in patients with bipolar disorder—Trait and state alterations and association with levels of cytokines and C-reactive protein. <i>Psychiatry Research</i> , 2018, 261, 383-390.	3.3	12
30	Glycogen synthase kinase-3 β in patients with bipolar I disorder: results from a prospective study. <i>Bipolar Disorders</i> , 2016, 18, 334-341.	1.9	8
31	Network meta-analysis of antidepressants. <i>Lancet</i> , 2018, 392, 1011.	13.7	8
32	Tricyclic antidepressants versus “active placebo”™, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. <i>Systematic Reviews</i> , 2021, 10, 227.	5.3	8
33	Glycogen Synthase Kinase-3 β : Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. <i>Neuropsychobiology</i> , 2016, 73, 108-115.	1.9	5
34	Glycogen synthase kinase-3 β activity and cognitive functioning in patients with bipolar I disorder. <i>European Neuropsychopharmacology</i> , 2018, 28, 361-368.	0.7	4
35	Duloxetine versus “active”™ placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. <i>Systematic Reviews</i> , 2021, 10, 171.	5.3	4
36	Caution should be advised when recommending increased use of ECT based on low-quality evidence. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 485-486.	4.5	3

#	ARTICLE	IF	CITATIONS
37	Substantial delays in clinical data published by the European Medicines Agency – a cross sectional study. <i>Journal of Clinical Epidemiology</i> , 2022, 146, 68-76.	5.0	3
38	Unconvincing evidence for peripheral biomarkers in major mental disorders. <i>Translational Psychiatry</i> , 2021, 11, 237.	4.8	2
39	Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives. <i>European Neuropsychopharmacology</i> , 2019, 29, S347-S348.	0.7	1
40	Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2443.	7.4	1
41	Electroconvulsive therapy for depression. <i>The Cochrane Library</i> , 0, , .	2.8	1
42	Caution is advised when interpreting subgroup analyses. <i>Neuropsychopharmacology</i> , 2021, 46, 1551-1551.	5.4	1
43	Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0260544.	2.5	1
44	Combination Antidepressant Therapy vs Monotherapy – Further Considerations. <i>JAMA Psychiatry</i> , 0, , .	11.0	1
45	A peripheral composite proteomic and gene expression biomarker related to diagnosis and affective state in rapid cycling bipolar disorder. <i>European Psychiatry</i> , 2016, 33, S123-S123.	0.2	0
46	Pharmacological treatments for generalised anxiety disorder. <i>Lancet, The</i> , 2019, 394, 1229.	13.7	0
47	Sertraline in primary care: comments on the PANDA trial. <i>Lancet Psychiatry, the</i> , 2020, 7, 18-19.	7.4	0
48	No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study. <i>Bipolar Disorders</i> , 2020, 22, 860-861.	1.9	0
49	Long-acting injectable versus oral antipsychotics for schizophrenia. <i>Lancet Psychiatry, the</i> , 2021, 8, 566-567.	7.4	0
50	Electroconvulsive therapy for acute affective episodes in people with bipolar disorder. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
51	Electroconvulsive therapy for preventing relapse and recurrence in bipolar disorder. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
52	Electroconvulsive therapy for preventing relapse and recurrence in people with depression. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
53	Adverse effects of electroconvulsive therapy. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
54	Title is missing!. , 2020, 15, e0237950.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0237950.		0
56	Title is missing!. , 2020, 15, e0237950.		0
57	Title is missing!. , 2020, 15, e0237950.		0